3M's $7.35 billion PFAS agreement puts most payments in 2028 to 2032
3M's agreement covers approximately 99% of current AFFF personal injury claims, while leaving mechanisms for remaining and future claims. The $5.8 billion present value commitment is payable over nine years through 2034, with most nominal payments concentrated in the middle of the schedule.
3M has agreed to a PFAS personal injury settlement involving $7.35 billion in nominal pre tax payments over nine years. The company release values the same commitment at $5.8 billion in present value. The less obvious finding is where the cash payments fall: the disclosed schedule puts most of the nominal total in 2028 to 2032.
Most payments fall in the middle years
3M expects to pay $50 million in 2026 and nothing in 2027. About 20% of the $7.35 billion nominal total is scheduled for the final two years, 2033 and 2034.
That implies approximately $1.47 billion in those final two years and, after the $50 million expected in 2026, approximately $5.83 billion in 2028 to 2032. On CTOL's arithmetic, roughly four fifths of the nominal commitment falls in those middle five years.
These are estimates derived from aggregate disclosures. The approximate final-two-year share makes the residual approximate. The schedule identifies the funding window but gives no breakdown of payments within those years.
3M described a 5.8 billion dollar present value commitment and 7.35 billion dollars of nominal pre tax payments.
View data
| Settlement measure | Billions of dollars |
|---|---|
| Present value commitment | 5.8 |
| Nominal pre tax payments | 7.35 |
What the settlement covers
The agreement covers approximately 99% of current personal injury claims inside and outside the AFFF multidistrict litigation. About 115,000 to 120,000 plaintiffs are eligible. Those figures describe the agreement's coverage and eligible population, rather than the number of completed claim resolutions.
The 3M investor release describes mechanisms for remaining and future claims, including a $680 million reserve within the overall commitment. The reserve is part of the framework, not a ceiling on all future PFAS exposure.
3M made no admission of liability and says it will defend litigation if the settlement terms are not fulfilled. Chief executive William Brown called the agreement a significant milestone that substantially reduces litigation uncertainty.
The company says PFAS compounds were phased out by 2000 and global manufacturing ended by the end of 2025. Its PFAS stewardship page provides its background; the agreement leaves broader environmental and legal exposure unresolved.
The accounting charge is not the cash payment
3M expects a $5.8 billion pre tax charge in the fourth quarter of 2026 and only $50 million in settlement cash payments that year. It says 2026 guidance remains unchanged.
The charge recognizes the present value commitment while actual payments extend through 2034. Unchanged guidance leaves the burden of later payments unresolved.
The missing comparison is 3M's capacity to fund the payments. The announcement gives no comparison with free cash flow or liquidity, so financial strain remains unresolved.
Scenarios
If eligible claimants participate and remaining claims use the announced mechanisms, 3M would gain visibility into current AFFF personal injury exposure. Payments on schedule would support that interpretation.
If future claims require obligations beyond the commitment or payments are revised, the reduction in uncertainty would be less complete. Any change needs a consistent nominal or present value basis.
The available figures provide no probabilities or date for full claimant participation. Later claimant and payment disclosures will distinguish execution of the agreement from additional exposure.
What settles it
The first accounting checkpoint is 3M's planned fourth quarter 2026 charge. Later claimant participation figures and payment reports can establish how much of the current claim pool has been resolved and whether expected obligations have changed.
A material upward revision to the expected present value commitment would weaken the case that the agreement has contained the cost of the identified exposure. The comparison must use the same basis. Payments and claim resolutions within the announced framework would support it.
The agreement substantially narrows uncertainty around current AFFF personal injury claims, but future claims and changes to expected payments will determine whether the stated commitment holds.